Cover image

Oncomedicine is an international journal publishing cutting edge research in oncology and medicine including translational oriented pre-clinical studies and clinical studies. The journal aims to promote novel concepts, new methods, new regimens, new therapeutic agents and medicine, and innovative or alternative approaches for the detection, intervention and treatment of human malignancies and relevant diseases.

Types of articles:

  • Review and mini-review
  • Promising clinical trial outcome
  • Novel therapeutic regimen and protocol
  • Novel hypothesis, device, method, and biomarker
  • Commentary and letter to editor
  • Research and short research communication
  • Scientific debate on controversial issues
  • Special issues addressing urgent medical problems

Short Research Communication
The Factors Reducing Relative Dose Intensity of Cisplatin and Vinorelbine as Adjuvant Chemotherapy in Patients with Non-Small Cell Lung Cancer
Ryo Inose, Katsuyuki Takahashi, Naruo Yoshimura, Tomoya Kawaguchi, Mitsutaka Takada, Katsuya Nagayama
Oncomedicine 2017; 2: 150-155. doi:10.7150/oncm.21294
[Abstract] [Full text] [PDF]

Review
Repurposing of Anthelminthics as Anticancer Drugs
Gerhard Hamilton, Barbara Rath
Oncomedicine 2017; 2: 142-149. doi:10.7150/oncm.20563
[Abstract] [Full text] [PDF]

Review
First and Best Treatments for EGFR and PD-L1 - Competition for First Line Therapy in Adenocarcinoma
Paul Zarogoulidis, Yan-Gao Man, Wolfgang Hohenforst-Schmidt, Lonny Yarmus, Haidong Huang, Chong Bai, Nikolaos Barbetakis, Christoforos Kosmidis, Chrisanthi Sardeli, Theodora Kerenidi, George Papatsibas, Theodora Tsiouda
Oncomedicine 2017; 2: 138-141. doi:10.7150/oncm.20759
[Abstract] [Full text] [PDF]

Review
BRCA 1/2 Tumors and Gene Expression Therapy for Breast Cancer Development and Metastasis
Anup P. Challa, Chikezie O. Madu, Yi Lu
Oncomedicine 2017; 2: 132-137. doi:10.7150/oncm.20393
[Abstract] [Full text] [PDF]

Review
The Position of Combination Chemotherapy with Mitomycin C and Methotrexate in the Treatment of Metastatic Breast Cancer - Especially Triple Negative Breast Cancer
Masahiko Tanabe, Takayo Fukuda, Yoshinori Ito
Oncomedicine 2017; 2: 126-131. doi:10.7150/oncm.21071
[Abstract] [Full text] [PDF]

Review
Malignant Pleura Mesothelioma: Clinical Perspectives
Konstantinos Grapatsas, Vasileios Leivaditis, Paul Zarogoulidis, Manfred Dahm, Ilias Stylianos Iliadis, Zoi Tsilogianni, Efstratios Koletsis, Emmanouil Dimopoulos, Ioannis Vasilikos, Georgios Rizos, Ektoras Gazos, Nikolaos G Baikoussis, Theodora Tsiouda, Nikolaos Barbetakis, Yan-Gao Man, Christoforos Kosmidis, Christophoros Kotoulas
Oncomedicine 2017; 2: 121-125. doi:10.7150/oncm.20980
[Abstract] [Full text] [PDF]

Research Paper
MicroRNA Profiling Of Oxaliplatin-Resistant HCT116 Colorectal Cancer Cells
Bustamin Kosmo, Kee Wah Lee, Muhammad Sufyan bin Masroni, Sharne Leong, Wei Ern Ong, Hong Lyn Wong, Yi Yun Chang, Evelyn SC Koay, Sai Mun Leong, Karen Tan
Oncomedicine 2017; 2: 111-120. doi:10.7150/oncm.20045
[Abstract] [Full text] [PDF]

Research Paper
In vitro single-strand DNA damage and cancer cell cytotoxicity effects of Temozolomide
Shruti Purohit, Devashree Jahagirdar, Azad Kumar, Nilesh Kumar Sharma
Oncomedicine 2017; 2: 102-110. doi:10.7150/oncm.18405
[Abstract] [Full text] [PDF]

Review
Colorectal Cancer from Molecular Pathways to Gene Therapy
Christoforos Kosmidis, Paul Zarogoulidis, George Efthimidis, Sofia Baka, Christoforos Efthimiadis, Ioannis Tzitzikas, Nikolaos Michalopoulos, Konstantinos Sapalidis, Yan-Gao Man, Isaak Kesisoglou
Oncomedicine 2017; 2: 93-101. doi:10.7150/oncm.19157
[Abstract] [Full text] [PDF]

Research Paper
Coexistence of Two Novel Mutations in CDKN2A and PMS1 Genes in a Single Patient Identifies a New and Severe Cancer Predisposition Syndrome
Marco Cassone, Leila Baghernajad Salehi, Gianluca Tedaldi, Michela Tebaldi, Valentina Zampiga, Michela Biancolella, Barbara Testa, Daniele Calistri, Gerarda Mastrogiorgio, Silvia Lanciotti, Maria Rosaria D'Apice, Giuseppe Novelli, Federica Sangiuolo
Oncomedicine 2017; 2: 88-92. doi:10.7150/oncm.19362
[Abstract] [Full text] [PDF]

Research Paper
Immunohistochemical Expression of Cyclin D1 in Invasive Ductal Carcinoma of Human Breast
Mahmoud Assem, Eman Ahmed Youssef, Radwa Mohammed Rashad, Mona Abdel-Hamed Yahia
Oncomedicine 2017; 2: 80-87. doi:10.7150/oncm.18416
[Abstract] [Full text] [PDF]

Research Paper
Role of TRF2 in efficient DNA repair, spheroid formation and Cancer Stem Cell maintenance
Arka Saha, SwatiShree Padhi, Madhabananda Kar, Shomereeta Roy, Prasanta Maiti, Birendranath Banerjee
Oncomedicine 2017; 2: 71-79. doi:10.7150/oncm.18373
[Abstract] [Full text] [PDF]

Short Review
Endobronchial Ultrasound (EBUS) for Local Drug Application: Future Methodology
Paul Zarogoulidis, Mina Gaga, Wolfgang Hohenforst-Schmidt, Haidong Huang, Chong Bai, Kaid Darwiche, Georgia Trakada, Xrysa Sardeli, Aggeliki Rapti, Lutz Freitag
Oncomedicine 2017; 2: 66-70. doi:10.7150/oncm.18003
[Abstract] [Full text] [PDF]

Short Research Paper
Concurrent Capecitabine and Radiation Therapy for High-risk Primary Breast Cancer
Uma Goyal, Tijana Skrepnik, Rajayogesh Davuluri, Michele B Ley, Pavani Chalasani, Rebecca K Viscusi, Lauren G Lebeau, Robert B Livingston, Justin Famoso, Victor J Gonzalez
Oncomedicine 2017; 2: 61-65. doi:10.7150/oncm.17910
[Abstract] [Full text] [PDF]

Review
Immunological Role of Vitamin D in Skin Diseases and Carcinoma
Kelley Yuan, Chikezie O. Madu, Yi Lu
Oncomedicine 2017; 2: 52-60. doi:10.7150/oncm.19262
[Abstract] [Full text] [PDF]

Review
Base Excision Repair Manipulation in Breast Carcinoma: A Prospective Avenue to Potentiate Genome Insulting Approach
Aayushi Jain, Sunny Yadav, Mohsein Beig, Shruti Purohit, Nilesh Kumar Sharma
Oncomedicine 2017; 2: 42-51. doi:10.7150/oncm.16758
[Abstract] [Full text] [PDF]

In this study, free BPD, non-targeted and folate-targeted PEGylated BPD-loaded liposomes were introduced to a metastatic breast cancer cell line (MDA-MB-231) in vitro. The liposomes were reproducibly synthesized and characterized for size, polydispersity index (PDI), zeta potential, stability, and BPD release kinetics. Folate competition tests, fluorescence confocal imaging, and MTT assay were used to observe and quantify targeting effectiveness. The toxicity of BPD before and after PDT in monolayer and 3D in vitro cultures with TNBC cells was observed. This study may contribute to a novel nanoparticle-mediated approach to target TNBC using PDT. more ...
Recent investigations by the National Cancer Institute have shown that almost 55% of women with defective BRCA genes develop breast cancer by age seventy. These genes play an important role in tumor suppression; their mutations can increase the probability of developing metastatic cancer. Hence, scientists have begun studying BRCA-targeted gene therapy as an effective treatment for breast cancer. This paper investigates the mechanisms of BRCA1 and BRCA2 gene expression therapy in patients with breast cancer. By approaching the disease and its biochemical implications, it seeks to review current treatment options and genetic studies. We discuss the critical role of the BRCA gene family in signaling pathways (including angiogenesis) and evaluate the impacts of the loss-of-function mutations associated with the aforementioned disease. With this, we make suggestions for future studies and optimal treatment plans. more ...
Results: Oxaliplatin-resistant HCT116 cells exhibited higher migration, invasion and tumorsphere formation compared to parental oxaliplatin-sensitive HCT116 cells. The oxaliplatin-resistant cells showed a distinct miRNA expression profile compared to the parental cells. The expression of miR-601, miR-222, miR-202 and miR-25 were verified by RT-qPCR to be increased in resistant cells. Bioinformatics analyses were used to identify potential target mRNAs of these 4 miRNAs. Conclusion: Results presented in this study provide evidence that oxaliplatin-resistance induces phenotypic changes in colorectal cancer and alterations in miRNA expression. Functional studies on the miRNAs and their target mRNA may enable the discovery of functional pathways to chemoresistance in colorectal cancer. more ...
Repurposing refers to the reuse of conventional drugs with distinct indications for new applications in order to speed up drug development by capitalizing on previous knowledge and safety data. A prominent example is the proposal to implement anthelminthics, such as mebendazole, niclosamide and pyrvinium pamoate, as novel anticancer drugs. Numerous studies have demonstrated activity of these agents against a wide variety of cancers, especially cancer stem cell-like subpopulations, by a host of different mechanisms which comprise inhibition of signaling pathways, of mitochondrial respiration, as well as of cellular stress responses and others. However, these anthelminthics were administered orally for the treatment of nematode infections and showed mostly poor resorption and, therefore, systemic toxicity data are frequently not available. more ...
Complete cure of metastatic breast cancer (MBC) remains difficult, despite the development of new drugs. Triple negative (TN) breast cancer, which is defined by lack of hormone receptor (estrogen and progesterone receptors) expressions and the absence of human epidermal growth factor receptor type 2 (HER2) overexpression, is especially associated with poor long-term outcomes as compared with other breast cancer subtypes. Therefore, many patients with TN-MBC eagerly await promising novel treatments for TN-MBC. While new drugs are being developed, several conventional drugs such as mitomycin C (MMC) and methotrexate (MTX) are being used less. We reviewed our previous reports on combination chemotherapy with MMC and MTX (MMC/MTX) after multiple treatments. For the MMC/MTX regimen, MMC 8 mg/m2 on day 1 and MTX 60mg/m2 on days 1 and 15 were administered intravenously every 4 weeks. more ...